

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

REMARKS

This communication is being filed in response to the Office Action dated February 25, 2004. Claims 1-24 are pending.

The Examiner has withdrawn Claims 1-14 and 20-24 from further consideration as being drawn to non-elected inventions.

Claims 15-19 are rejected under the first paragraph of 35 U.S.C. § 112 for lack of enablement. Claims 16 and 19 are amended herein as described above. Applicants respectfully traverse the rejections of the aforementioned claims, as presently amended, for the reasons set forth below.

I. The Claims, as Presently Amended, are Enabled

Claims 14-19 are rejected under the first paragraph of 35 U.S.C. § 112 because, according to the Examiner, the specification does not enable any person skilled in the art to which the invention pertains, or with which it is most nearly connected, to make and use the invention commensurate with the scope of these claims. Specifically, the Examiner contends that the claims are broadly drawn to a method for stimulating pancreatic regeneration in a subject having a pancreatic disorder comprising administering bone marrow cells to said subject in an amount sufficient to result in the production of pancreatic cells.

According to the Examiner, the sole purpose of the present invention is to attain a therapeutic effect. The Examiner contends that the demonstration, in the instant application, of the presence of DPPIV-positive cells in the pancreata of DPPIV-deficient rats after the intravenous injection of bone marrow cells from DPPIV-positive donors is not sufficient for Applicants to conclude either 1) that the observed DPPIV-positive cells are capable of

differentiating or proliferating into any pancreatic cell types in sufficient numbers to yield any therapeutic effects for a subject having a pancreatic disorder, or 2) that the observed DPPIV-positive cells are capable of resulting in the production of a sufficient number of pancreatic cells in any mysterious manner to yield the desired therapeutic effects in a subject having a pancreatic disorder.

Applicants respectfully disagree. Applicants first note that the Examiner does concede that the instant application conclusively demonstrates that intravenous injection of bone marrow cells results in the presence of injected cells within the pancreas of the recipient. Applicants also note that the instant application teaches that bone marrow cells can be obtained by standard bone marrow aspiration techniques known in the art (p. 11, lines 3-4), and that bone marrow cells can be enriched for stem cells prior to administration to a recipient (p. 11, lines 11-12). Furthermore, Applicants' specification teaches that bone marrow cells can be stimulated, either *in vitro* prior to readministration or *in vivo* after readministration, to stimulate proliferation, differentiation, or gene expression in the bone marrow cells (p. 11, lines 20-22). Applicants assert that the details of these teachings are well known to those in the art of bone marrow isolation, enrichment and culturing. Moreover, Applicants teach that bone marrow cells *of the instant invention* (e.g., those that have been isolated, enriched, and proliferated or differentiated *in vitro* or *in vivo*) may be used for the regeneration of tissues other than liver (p. 17, lines 16-17). Thus, Applicants conclude that one of ordinary skill in the art, supplemented by the teachings of the instant invention, would be able to isolate bone marrow cells and to introduce the bone marrow cells into recipients, and that these bone marrow cells could, according to the teachings of the instant invention, proliferate or differentiate in response to various environmental stimuli present either *in vitro* or *in vivo*.

It is not surprising, therefore, that Applicants, using the teachings of the instant invention and techniques well known to those of ordinary skill in the art of bone marrow isolation, enrichment, and culturing, and in the treatment of pancreatic deficiencies, were able to employ bone marrow cells to obtain pancreatic-like cells that, when implanted under the kidney capsule of chemically-induced diabetic mice, permitted complete normalization of blood glucose levels and long-term survival. *See* Oh S, Muzzonigro TM, Bae SH, LaPlante JM, Hatch HM, Petersen BE. Adult bone marrow-derived cells trans-differentiating into insulin-producing cells for the treatment of type I diabetes. *Lab Invest.* 2004 May;84(5):607-617 (Exhibit A). These studies conclusively demonstrate that bone marrow cells can in fact serve as a source for the production of a sufficient number of pancreatic cells to exert a therapeutic effect in recipients into which the cells have been implanted. These studies suggest that similar exposure of the pancreatic DPPIV-positive cells of the instant invention to high glucose *in vivo*, *e.g.* in animals that were diabetic at the time of bone marrow cell infusion, would lead to a similar amount of proliferation and differentiation of the bone marrow cells as observed *in vitro* in the study of Oh *et al.* Thus, Applicants assert that the teachings of the instant application are in fact enabling for a method for stimulating pancreatic regeneration in a subject having a pancreatic disorder comprising the administration of bone marrow cells to the subject in an amount sufficient to result in production of pancreatic cells (Claim 15). Applicants further assert that the teachings are enabling for the introduction of these bone marrow cells by intravenous injection (Claim 16 as amended) or by transplantation into the pancreas, either without (Claim 17) or with (Claim 19 as amended) a support matrix.

Regarding the Examiner's other points, Applicants agree that introduction of antigenically mismatched cells or tissues may sometimes be accompanied by strong adverse host

immune responses against the transplanted cells or tissues. However, Applicants contend that the scientific literature, at the time of filing of the instant application, was replete with examples demonstrating the efficacy of adjunct immunomodulatory treatments in reducing or abrogating these responses, thereby prolonging survival of the implanted cells. *See e.g.*, Liu C, Deng S, Yang Z, Kucher T, Guo F, Gelman A, Chen H, Naji A, Shaked A, Brayman KL. Local production of CTLA4-Ig by adenoviral-mediated gene transfer to the pancreas induces permanent allograft survival and donor-specific tolerance. *Transplant Proc.* 1999 Feb-Mar;31(1-2):625-6 (Exhibit B); Namii Y, Hayashi S, Yokoyama I, Kobayashi T, Yasutomi M, Nagasaka T, Uchida K, Hamada H, Takagi H. Evidence that the adenoviral vector containing the CTLA4-Ig gene improves transgene expression and graft survival. *Transplant Proc.* 1997 May;29(3):1738-9 (Exhibit C). Applicants therefore assert that the artisan of ordinary skill, based on the teachings of the instant application combined with the knowledge provided by the prior art, would be able to practice the instant invention as claimed without undue experimentation.

The Examiner also asserts that the specification is not enabling for introducing the bone marrow cells by any route of delivery. Applicants rely on the teachings of the prior art at the time of filing in support of the fact that engraftment of bone marrow cells into the pancreas could be achieved by several different routes, including but not limited to intravenous injection and direct intrapancreatic injection. However, in the interests of obtaining rapid allowance of claims, and not conceding the correctness of the Examiner's position that undue experimentation would be required for the artisan of ordinary skill to practice the instant invention using various routes of administration of bone marrow cells, Applicants have amended Claim 16 to indicate that the bone marrow cells are injected intravenously. Applicants also have amended Claim 19 so that it depends from Claim 17 rather than Claim 15.

The final area of disagreement concerns Claim 18. The Examiner alleges that this claim is not enabled because, according to the Examiner, the attainment of any therapeutic effects via gene therapy (including *in vivo* and *ex vivo* gene therapy) in general remains unpredictable as evidenced by the teachings of Dang *et al.* and Romano *et al.* Applicants respectfully submit that many examples of the successful application of gene transfer, either *ex vivo* or *in vivo*, could be found in the scientific literature at the time of filing of the instant application. *See e.g.*, Liu C, Deng S, Yang Z, Kucher T, Guo F, Gelman A, Chen H, Naji A, Shaked A, Brayman KL. Local production of CTLA4-Ig by adenoviral-mediated gene transfer to the pancreas induces permanent allograft survival and donor-specific tolerance. *Transplant Proc.* 1999 Feb-Mar;31(1-2):625-6 (Exhibit B); Namii Y, Hayashi S, Yokoyama I, Kobayashi T, Yasutomi M, Nagasaka T, Uchida K, Hamada H, Takagi H. Evidence that the adenoviral vector containing the CTLA4-Ig gene improves transgene expression and graft survival. *Transplant Proc.* 1997 May;29(3):1738-9 (Exhibit C). Thus, Applicants contend that Claim 18 is in fact enabled by the teachings of the instant application in combination with the knowledge provided by the prior art to the artisan of ordinary skill.


CONCLUSIONS

In light of the amendments, Applicants submit that the present application is in condition for allowance of Claims 14-19. A Notice of Allowance is therefore respectfully requested.

Applicant respectfully petitions for a two-month extension of time. A check in the amount of \$210.00 is enclosed. Should any additional fees be required in connection with this filing, the Commissioner is hereby authorized to charge Deposit Account Number 02-4377. Two copies of this communication are enclosed.

Respectfully submitted,

BAKER BOTTS L.L.P.



Rochelle K. Seide

Patent Office Reg. No. 32,300

Carmella L. Stephens

Patent Office Reg. No. 41,328

Attorneys for Applicant

Randy C. Eisensmith

Patent Office Reg. No. 55,146

Agent for Applicant

30 Rockefeller Plaza

New York NY 10112-4498

(212) 408-2585

Adult bone marrow-derived cells trans-differentiating into insulin-producing cells for the treatment of type I diabetes

Seh-Hoon Oh¹, Toni M Muzzonigro¹, Si-Hyun Bae¹, Jennifer M LaPlante¹, Heather M Hatch¹ and Bryon E Petersen²

¹Department of Pathology, Immunology and Laboratory Medicine and ²Program in Stem Cell Biology and Regenerative Medicine, College of Medicine, University of Florida, Gainesville, FL, USA

Recent findings suggest that bone marrow (BM) cells have the capacity to differentiate into a variety of cell types including endocrine cells of the pancreas. We report that BM derived cells, when cultured under defined conditions, were induced to trans-differentiate into insulin-producing cells. Furthermore, these insulin-producing cells formed aggregates that, upon transplantation into mice, acquired architecture similar to islets of Langerhans. These aggregates showed endocrine gene expression for insulin (I and II), glucagon, somatostatin and pancreatic polypeptide. Immunohistochemistry also confirmed that these aggregates were positive for insulin, somatostatin, pancreatic polypeptide and C-peptide. Also, Western and ELISA analysis demonstrated expression of proinsulin and/or secretion of active insulin upon glucose challenge. Subcapsular renal transplantation of these aggregates into hyperglycemic mice lowered circulating blood glucose levels and maintained comparatively normal glucose levels for up to 90 days post-transplantation. Graft removal resulted in rapid relapse and death in experimental animals. In addition, electron microscopy revealed these aggregates had acquired ultrastructure typically associated with mature beta (β) cells. These results demonstrate that adult BM cells are capable of trans-differentiating into a pancreatic lineage *in vitro* and may represent a pool of cells for the treatment of diabetes mellitus.

Laboratory Investigation (2004) 84, 607–617, advance online publication, 22 March 2004; doi:10.1038/labinvest.3700074

Keywords: bone marrow cell; C-peptide; diabetic therapy; insulin; trans-differentiation

Stem cells are self-renewing elements that can generate many cell types in the body and are found in both adult and fetal tissue. Cell therapy using stem cells and their progeny is a promising approach that may be capable of addressing many unmet medical needs.¹ Recently, stem cell research has quickly progressed, allowing researchers to isolate and purify stem/progenitor cell populations from various tissues (ie hematopoietic, vascular endothelial and neural stem cells, as well as hepatic oval cells).^{2–4} Bone marrow (BM)-derived cells have been shown to differentiate into

various lineages, such as hepatocytes, *in vivo* and *in vitro*.^{5–7} As stem cell research progresses, new methods for the therapy and treatment of diseases such as diabetes mellitus may be possible. In addition, stem cell research may advance our understanding of organ regeneration and the mechanism(s) thereof.

The pancreas is composed of two compartments, the exocrine and endocrine, which have very distinct functions. The endocrine compartment consists of islets of Langerhans, which are composed of clusters of four cell types that synthesize the peptide hormones: insulin (β -cells), glucagon (α -cells), somatostatin (δ -cells) and pancreatic polypeptide (γ -cells). These cells have been shown to differentiate from ductal epithelial stem cells through sequential differentiation during embryogenesis.^{8–10}

Type I diabetes results when the β -cells of the pancreas are destroyed by T-cells of the immune system, which markedly reduce the number of

Correspondence: BE Petersen, Department of Pathology, PO Box 100275, University of Florida, Gainesville, FL, 32610, USA.
E-mail: petersen@pathology.ufl.edu

SHO and BEP are inventor/coinventor of a patent(s) related to this technology and may benefit from royalties paid to the University of Florida related to its commercialization.
Received 12 December 2003; revised 10 February 2004; accepted 11 February 2004; published online 22 March 2004

β -cells resulting in lower insulin production. The worldwide prevalence of Type I diabetes is rapidly increasing and considerable interest has developed in finding mechanisms that may increase active insulin secretion. Various endeavors to solve this challenge have been made through stimulating the endogenous regeneration of islets and through transplantation of donor islets or *in vitro*-differentiated islet-like cells.^{11–14}

Recent reports have described a multipotent stem cell within the pancreas.¹⁵ These cells have the capacity to differentiate into pancreatic islet-like structures *in vitro*. Furthermore, other cell types, such as hepatic oval cells and embryonic stem cells are also capable of differentiating into pancreatic endocrine hormone-producing cells both *in vitro* and *in vivo*.^{16–18}

Current research, attention has focused on the possible use of the controlled differentiation of stem cells to obtain specialized cells useful in treating many diseases. Here, we show that BM-derived cells can be efficiently induced to differentiate into insulin-producing cells, as well as other cell types, typical of endocrine pancreas. In addition, these cells self-assemble to form functional pancreatic islet-like structures. The insulin-producing cell clusters isolated from BM cells demonstrated reversal of hyperglycemia when implanted into a chemically induced diabetic NOD/*scid* mouse model. In addition, these cells acquire ultrastructural characteristics typical of a mature β -cell phenotype. The data provided may allow for the treatment of diabetes via a stem cell therapy approach.

Materials and methods

BM Cell Culture

All procedures regarding animals were conducted according to institutionally approved protocols and guidelines. BM cells were collected from the long bones of F-344 rats (Harlan, Indianapolis, IN, USA). The BM cells were cultured in DMEM supplemented with 10% FBS. After 60 min of incubation, nonadherent cells were collected and washed with fresh, serum-free DMEM medium. The cells were replated in serum-free DMEM medium at a cell density of $1 \times 10^7/\text{cm}^2$ in the presence of 1% DMSO. The cells were then cultured in DMEM supplemented with 1% DMSO for 3 days followed by either high (25 mM) or low (5.5 mM) glucose DMEM media supplemented with 10% FBS for 7 additional days. They were plated in plastic six well plates on slide coverslips ($22 \times 22 \text{ mm}^2$) coated with 0.3% type I collagen, which was extracted from the rat-tail tendon by the method described by Michalopoulos and Pitot.¹⁹

Detection of Transcription Factors, Glut-2 and Pancreatic Endocrine mRNAs

Total RNA was isolated from the adult rat pancreas and BM cells treated with 1% DMSO/DMEM low glucose medium (Day 3), DMEM high glucose medium with 10% FBS (days 7 and 10), or nonculture BM cells by the RNeasy kit (Qiagen, Valencia, CA, USA). A measure of $2 \mu\text{g}$ RNA was used for cDNA synthesis. RT-PCR was performed as previously described by Yang *et al.*¹⁶ The resulting products were amplified, electrophoresed in 1.5% agarose gels containing EtBr, and purified by gel elution. These products were directly sequenced using an AmpliTaq cycle sequencing kit (Perkin-Elmer Setus, Branchburg, NJ, USA) for genetic confirmation.

Analysis of Insulin Gene Expression by Northern Blot

Total RNA was extracted from phosphate-buffered saline (PBS)-washed BM-derived cluster cultures, using RNA-Bee (Tel-Test, Inc. TX, USA) and purified per the manufacturer's guidelines. RNA concentration and purity were determined by routine spectrophotometry. Samples of RNA ($25 \mu\text{g}/\text{lane}$) were size fractionated on 1% agarose gels and transferred to nylon membranes (Amersham, Arlington Heights, IL, USA) by capillary action. After crosslinking under UV light, membranes were prehybridized and then hybridized overnight with specific insulin cDNA that had been labeled with [α -³²P]dCTP using an Amersham random primer kit. Membrane was subsequently washed under high-stringency conditions and exposed to X-omat film (Kodak, NY, USA).

In Situ Hybridization (ISH) with Digoxigenin-Labeled DNA Probes (Boehringer Mannheim)

Frozen sections of $6 \mu\text{m}$ thickness were fixed for 15 min in 4% paraformaldehyde. Rat insulin digoxigenin-labeled DNA probe (Roche, Indianapolis, IN, USA) was denatured at 80°C for 5 min and applied to sections at 52°C . The sections were coverslipped and sealed with rubber cement for incubation overnight in a hydrated slide box at 52°C . The following day, the coverslips were carefully removed in preheated $2\times$ SSC buffer, pH 7.0, at 65°C . The sections were gently washed twice in preheated 50% formamide in $5\times$ SSC buffer for 5 min each at room temperature and were then gently washed twice in preheated $0.1\times$ SSC buffer for 5 min each at 65°C . Color development was performed at room temperature in buffer (Tris 100 mM, NaCl 100 mM and MgCl_2 50 mM, pH 9.5) containing NBT and BCIP (Roche). Sections were counterstained with nuclear fast red (Vector Laboratories, Burlingame, CA, USA) and mounted in Cytoseal (Richard-Allan Sci. Kalamazoo, MI, USA).

Immunocytochemistry

Immunoactivity was detected using the cytochemical method described by Oh *et al.*⁷ Trans-differentiated BM-derived cells were grown on coated coverslips until spheroid colonies formed at approximately 10 days of culture. Individual clusters were retrieved, frozen in OCT at -70°C , cut into $6\text{ }\mu\text{m}$ sections and placed on Superfrost Plus slides. Sections were then fixed in a 4% paraformaldehyde/PBS solution at room temperature for 15 min. The slides were further treated with a 5% skim milk in TBS-Ca blocking medium for 1 h. These slides were incubated overnight at 4°C with one of the following: anti-human Insulin (Dako, Carpinteria, CA, USA), anti-rat insulin (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), anti-human pancreatic polypeptide (Dako), anti-rat somatostatin (Santa Cruz), or anti-rat C-peptide (Linco Research Inc., St Charles, MI, USA) diluted at 1:100. Sections were washed with TBS-Ca, samples were incubated at 4°C for 3 h with secondary antibody: anti-rabbit IgG Texas Red-conjugated, anti-guinea pig IgG Texas Red-conjugated, anti-rabbit IgG Fluoresceine (FITC) conjugated or anti-goat IgG FITC conjugated (Santa Cruz, CA, USA) at a 1:100 dilution with DAPI (Vecter Lab. Burlingame, CA, USA) for nuclear staining. The sections were then photographed using an Olympus microscope and Optronics Digital camera (Olympus, Melville, NY, USA) or a MRC 1024 GS confocal microscope (Bio-Rad, Hercules, CA, USA).

Measurement of Insulin Content and Secretion by Immunoprecipitation-Western Blotting and ELISA

BM cells were cultured in the presence of 1% DMSO for 3 days, and changed to DMEM with 4.5 g/l glucose and 10% FBS for 7 days. The medium was then changed to serum-free medium containing 0.5% BSA and 5.5 mM glucose to enable the detection of insulin secretion without interference from the fetal serum. The cells were incubated in this condition for 5 h at 37°C followed by washing twice with additional serum-free medium. High-glucose challenge of the cells was achieved by the addition of serum-free media containing 25 mM glucose for a 2 h at 37°C . The conditioned media was collected and frozen at -20°C until assayed for insulin content. Intracellular insulin was detected by cell extraction with lysis buffer and a combination of immunoprecipitation and Western blotting, as detailed by Yang *et al.*¹⁶ Specifically, the presence of insulin in the culture media and cells lysates was determined by immunoprecipitation with a rabbit polyclonal antiinsulin antibody (Santa Cruz Biotechnology) followed by separation of the precipitated material by SDS-PAGE on 18% gels, transfer to nylon membranes, and blotting with anti-insulin antibody. A measure of 150 μg of cell lysate or 1 ml of culture media was subjected to immunoprecipita-

tion. Normal rabbit serum was used as primary antibody control and culture medium containing 0.5% BSA was used as a control for secreted insulin measurements. Insulin protein was visualized by chemiluminescence. ELISA was performed on the conditioned media to determine insulin secretion using the 1-2-3 Ultra-Sensitive Rat Insulin ELISA kit following the manufacturer's instructions (ALPCO Diagnostics, Windham, NH, USA).

Insulin-Producing Cell Transplantation and Physiological Tests

Hyperglycemia was induced in 10-week-old male NOD/*scid* mice (The Jackson Laboratory, Bar Harbor, ME, USA) through intraperitoneal injection of 40 mg/kg of streptozotocin (STZ) once a day for five consecutive days as described by Yang *et al.*¹⁶ Blood glucose level was determined using a standard blood glucose meter (One touch profile, Johnson and Johnson Com., Milpitas, CA, USA). Stable hyperglycemia (blood glucose levels ranging between 300 and 600 mg/dl) developed 5–6 days following the last STZ injection.

Under general anesthesia, mice received a renal subcapsular transplant of 150 insulin-producing clusters ($n=9$), a sham transplant of saline solution ($n=10$) or 10 million noncultured BM cells ($n=3$) in the right subcapsular renal space. Blood glucose levels were monitored every 2 days after transplantation for 17 days. Grafts were then removed by unilateral nephrectomy to test for euglycemia reversal and glucose monitoring continued ($n=6$).

Immuno-gold Labeling and Electron Microscopy

Insulin-producing cell clusters were fixed in 0.1% glutaraldehyde/2% formaldehyde in 0.1 M cacodylate buffer, transferred to 0.1 M cacodylate buffer, and embedded. Ultrathin sections were sequentially treated with 10% H_2O_2 , washed with 0.9% NaCl, blocked with 3% BSA, incubated overnight with the primary antibody in PBS supplemented with 0.5% BSA (rabbit anti-rat insulin, 1:100, Santa Cruz), washed with PBS, and reblocked with goat serum. Binding of the primary antibody was visualized with gold-labeled secondary antibody (15-nm gold particles, goat-anti-rabbit, Amersham Pharmacia, Piscataway, NJ, USA), followed by counterstaining of the sections for electron microscopy.

Results

BM-Derived Cells Trans-Differentiation into Endocrine Cells

BM cells were plated on 0.3% rat tail collagen (RTC) coated coverslips contained within six-well culture dishes. BM cells were cultured with 1% dimethyl sulfoxide (DMSO) in serum-free DMEM for 3 days

and then maintained for an additional 7 days in a DMSO-free DMEM medium containing 10% FBS with either a low (5.5 mM) or high (25 mM) concentration of glucose. Cells cultured under high-glucose conditions began to form small spheroid clusters at approximately day 7 (Figure 1a). Following day 10, under the same conditions, the number and dimension of these spheroid cell clusters were markedly increased (Figure 1b and c). The three-dimensional cell growth morphology closely resembled islet-like clusters, as previously described by other investigators.^{13,15,16} The results of the experimental approach using either low- or high-glucose medium in inducing spheroid formation are summarized in Figure 1d. The number of clusters formed in low-glucose culture conditions on a $22 \times 22 \text{ mm}^2$ coverslip was 17 ± 11.3 . However, under high-glucose condition the number of clusters obtained were 157 ± 32.9 (Figure 1d). Also, it should be noted that the cluster size under low-glucose conditions was considerably smaller as compared to that of high-glucose condition (data not shown). Based on the culture conditions and the harshness of the first 3 days, we looked at viability of the BM

cells. At time zero, 2-h postculture the viability of these cells was at 95% by Trypan blue-exclusion technique. The cells at day 3 of culture (1% DMSO-serum free) revealed that the cells were 97.6% viable by Trypan blue-exclusion and propidium iodide (PI) FACS analysis. Lastly, we examined the clusters formed in culture (day 10) for cell viability. The clusters were disassociated and examined by Trypan blue-exclusion at PI FACS. The assays revealed very little cell death within the formed clusters with cell viability in the 99% range. Thus, the harshness of the culture conditions (3 days in serum-free 1%-DMSO media) did appear to select for a subpopulation of BM cells, which, when switched to a high-glucose serum-supplemented media, were able to proliferate and form clusters.

Gene Expression of Endocrine Cell Markers by the BM-Derived Clusters

To determine whether the islet-like clusters appearing in the BM-derived cell cultures may have trans-differentiated into endocrine hormone-producing




Figure 1 BM cells differentiated into pancreatic-like cells via *in vitro* culture system. Trans-differentiation of BM cells under conditions, which induce an endocrine cell phenotype: BM cells cultured in the serum-free medium for 3 days in 1% DMSO then cultured in the 10% FBS and high glucose (25 mM) for an additional 4 days. Small clusters begin to form and continued to expand forming a tightly organized mass of cells (a). Multiple clusters can be seen in single fields (b), and at higher magnifications they appear to have defined edges and structure (c). Low-glucose conditions produce 17.3 ± 11.3 clusters while high-glucose conditions for 10 days gave a mean value of 157.5 ± 32.9 clusters ($n = 8/22 \times 22 \text{ mm}^2$ coverslips, three separate experiments) clusters (d). Original magnification for (a) and (c): $\times 40$, with magnification for (b): $\times 20$.

cells, the expression of endocrine cell genes was examined by RT-PCR. In order to ascertain whether pancreatic lineages are originally present in the bone marrow, we tested total RNA extracted from freshly isolated BM cells by RT-PCR for gene expression of pancreatic specific transcription factors and the Glut-2 and endocrine genes. Transcription factors, Glut-2 and endocrine pancreatic mRNAs were not detected in the freshly isolated BM cells at day 0 (Figure 2a and b, D0). However, when BM cells were cultured with 1% DMSO for 3 days, PDX-1, NKX2.2 and NKX6.1 messages were strongly expressed (Figure 2a, D3). Furthermore, the Glut-2 gene was not expressed in D0 and D3, but the message was expressed following the change to high-glucose culture medium (Figure 2a days 7 and 10). Endocrine messages demonstrate that expression of genes occurred in BM cell cultures treated with 1% DMSO. Insulin (I and II), glucagon, somatostatin and pancreatic polypeptide mRNAs were detected during the initial 3 days of culture (Figure 2b, D3). Further investigation of cultures in high-glucose DMEM with 10% FBS also showed the expression of these mRNAs at days 7 and 10 (Figure 2b). These PCR products were further analyzed by sequencing and compared to GenBank for confirmation (data not shown).




Figure 2 Pancreatic gene expression in noncultured and cultured BM derived cells. RT-PCR analysis for expression of transcription factors, Glut-2 (a) and pancreatic endocrine genes (b) in adult pancreas (control), noncultured BM-derived cells and cultured BM-derived cells.

In addition, we also examined the mRNA expression for insulin by Northern blot and *in situ* hybridization of BM-derived clusters. Figure 3a shows the presence of insulin mRNA in cultured BM-derived insulin-producing clusters and INS-1 cells (positive control), but fresh BM cells did not express insulin message. Expression of the insulin gene was also examined by ISH of the BM-derived clusters. Figure 3b represents ISH for insulin on noncultured BM cells. As seen in the figure the noncultured BM cells are negative for insulin expression. While Figure 3c indicates the presence of the insulin expression in INS-1 cells (positive control). Figure 3d and e show the presence of




Figure 3 Northern blot and ISH analyses of expression of insulin message in cultured BM cells. (a) Insulin mRNA levels in BM derived cells: Northern analysis for expression of insulin mRNA in normal liver (negative control), INS-1 cell (positive control), cultured BM derived cells and noncultured BM-derived cells. (b-e) ISH of insulin mRNA in whole BM cells (b; Negative control), INS-1 cell (c; Positive control) and frozen sections of clusters (d and e). ISH analysis at low and high magnifications (d and e). The cells are positive for insulin mRNA expression (blue) and counter stained with nuclear fast red. (b-d) photomicrographs were taken using $\times 60$ and $\times 100$ oil immersion objectives, respectively.

insulin mRNA in the cytoplasm of the BM-derived clusters using a DIG-labeled insulin-oligonucleotide probe. Insulin mRNA is clearly visible in a majority of the cells within the BM-derived clusters. These results indicate that BM-derived clusters may possess the potential to trans-differentiate into cells found within the islets of Langerhans.

Protein Analysis of BM-Derived Insulin-Producing Cells

To investigate the expression of pancreatic hormones, immunofluorescence analyses was performed for insulin, somatostatin and pancreatic polypeptide in BM-derived clusters. BM cells cultured with DMSO and under high-glucose condition were capable of cluster formation. The islets of Langerhans in normal pancreas were shown to strongly express insulin (Figure 4a). Furthermore, other cells found in islets of Langerhans express somatostatin (Figure 4b) and pancreatic polypeptide (Figure 4c). Figure 4d represents noncultured BM stained for insulin. In addition, immunofluorescence was performed for somatostatin and pancreatic polypeptide revealing no positive staining (data not shown). However, the BM derived insulin-producing clusters did express these cytoplasmic proteins (Figure 4e–g). In these BM-derived cells, a higher number of insulin-positive cells were observed, corresponding to approximately 80% of the total cell population (Figure 4e). As expected, the number of insulin-positive cells observed was significantly higher than the number of cells expressing either somatostatin (Figure 4f) or pancreatic polypeptide (Figure 4g).

The trans-differentiated BM-derived cells, or insulin-producing clusters, synthesize and store detectable amounts of insulin during glucose challenge as determined by immunoprecipitation and Western blot analysis (Figure 5a). It was found that during glucose challenge, the cell lysate of the insulin-producing cell clusters contained proinsulin, while the media revealed the two-chain form of insulin. In addition to the Western analysis, we performed an ELISA assay to quantify the insulin being released into the media. In two separate experiments, BM-derived insulin-producing cell clusters (approx. 90 clusters per experiment) were challenged with 25 mM glucose for 2 h which resulted in secretion of roughly 186 ng/ml of insulin into the media (Figure 5b). However, cells cultured in a low-glucose media (5.5 mM) as well as media alone, showed no insulin reactivity (Figure 5b).

In addition, we also assessed the C-peptide expression of the BM-derived insulin producing clusters. Cells positive for C-peptide staining were seen throughout the clusters (Figure 6c–e). A comparison of the C-peptide staining pattern of a positive control cell line, INS-1, which overexpresses insulin (Figure 6a and b), to our insulin-




Figure 4 Immunofluorescence reveals BM-derived cells differentiated into pancreatic-like *in vitro*. Immunohistochemistry for insulin (a; Texas red) and double staining of insulin (Texas Red) with somatostatin (b; FITC) or pancreatic polypeptide (c; FITC) on normal pancreas, and nonculture BM cells counterstained using DAPI (blue) for nuclear staining; no immunostaining is observed (d). Immunofluorescence staining for insulin (Texas Red) on whole mount in BM derived cells, day 10 and frozen section of isolated cluster at $\times 40$: insulin immunoreactivity is present in the spheroid (e). Confocal photomicrographs of dual immunofluorescence for insulin (Texas Red) with somatostatin (FITC) or pancreatic polypeptide (FITC) on frozen sections of BM-derived cells, (f and g respectively). Original magnification is (b and d), $\times 40$ and (c), $\times 20$ objective. Photomicrographs for (f) and (g) were taken on MRC 1024 GS confocal microscope using a $\times 60$ oil immersion objective (f), and a $\times 40$ (g) objective.

producing cells, showed a pattern of staining similar in nature. We also examined this immunohistostaining using deconvolution microscopy (Delta Vision, Applied Precision Inc. WA, USA) to pinpoint the C-peptide staining within the cytoplasm of our insulin-producing cells (Figure 6e). These results suggest that BM-derived clusters may possess the function of insulin secretion during glucose challenge, as well as displaying morphology similar to Langerhans islets.




Figure 5 Analysis of secretion of insulin following glucose challenge in BM derived clusters cultures. (a) Western-blot analysis of insulin secretions measured following collection of cell lysates and culture-conditioned media. (b) ELISA assay for insulin in conditioned media from BM-derived cells exposed to low- (5.5 mM) or high- (25 mM) glucose conditions for 2 h. After exposure to high glucose both H9-2 (83 clusters) and H8-2 (94 clusters) showed secretion of insulin into the media (177.8 and 196.0 ng/ml, respectively). Whereas, the BM-derived cells exposed to low-glucose conditions and media alone showed no reactivity to insulin in the assay.

Rescue and Survival of Chemically Induced Diabetic Mice Following Insulin-Producing Cell Transplantation

Previous studies have shown that maturation to functional islet cells *in vitro* requires implantation into an *in vivo* environment.¹⁵ The ability of insulin-producing cells to reverse hyperglycemia was examined *in vivo* using a STZ-induced diabetes NOD/*scid* mouse model. Multiple treatments of STZ chemically induced a diabetic state in NOD/*scid* mice. Nine diabetic mice received roughly 150 BM-derived insulin-producing clusters transplanted into the renal subcapsular space. The mice receiving the transplant began to normalize their blood glucose levels within 2–3 days (Figure 7). Approximately 17 days post-transplantation, six of the nine mice underwent a nephrectomy to remove the graft. As seen in the graph, these animals became hyperglycemic and died shortly thereafter. The animals that retained the transplanted insulin-producing clusters maintained fairly normal glucose levels for the remainder of the study. Our results suggest that the clusters hold the potential to mature into fully functioning-endocrine cells similar to the islets of the pancreas. Control animals that did not receive implants or received noncultured BM cells




Figure 6 C-peptide analysis of BM-derived cells. Frozen sections of BM-derived cells were immunostained in order to determine the presence of processed proinsulin, which is C-peptide. INS-1 cells (a and b, positive control), BM-derived cells (c, d and e) were immunostained for C-peptide. As seen in the high-magnification photomicrograph (d), the cells within the cluster show distinct staining similar to the INS-1 positive control cells (b). Deconvolution microscopy was used to pinpoint the C-peptide staining within the cytoplasm of our insulin-producing cells (e). Original magnifications are as follows: (a) and (c): $\times 40$ and (b) and (d): $\times 60$, (e) $\times 100$ oil immersion.

exhibited persistent hyperglycemia followed by death.

The kidneys that received transplants were excised and further analyzed by conventional hematoxylin/eosin staining, immunohistochemistry, and ISH for insulin expression (Figure 8). Histology of the kidney capsules from animals that received a transplant of insulin-producing clusters was examined (Figure 8b). As seen in the photomicrograph the transplanted clusters were able to engraft under the capsule. The transplanted clusters were positive for insulin by immunohistochemistry (Figure 8c), and insulin gene expression was confirmed by ISH (Figure 8d). Normal kidney tissue, which did not receive a cluster transplant did not hybridize with the insulin probe demonstrating the specificity of the probe for insulin mRNA (Figure 8e). These results show that insulin-producing clusters retain their ability to secrete insulin *in vivo* and respond to the high-blood glucose levels in the diabetic mice.




Figure 7 Transplantation of insulin-producing cells into STZ-treated diabetic NOD/*scid* mice. To ascertain the functionality of these insulin-producing clusters and determine the changes of blood glucose levels over time, insulin-producing cells were transplanted into chemically induced diabetic mice. Shown in the graph are control STZ-treated mice transplanted with saline ($n=10$) or noncultured BM-cells ($n=3$), and mice transplanted with approximately 150 BM-derived insulin-producing clusters ($n=9$). In order to determine whether the transplanted clusters were responsible for the normalization of glucose levels, the insulin-producing cell transplanted mice were separated into two groups. One group was allowed to maintain the transplanted graft (non-nephrectomy; $n=3$), while the second group of transplanted mice underwent a nephrectomy (graft/nephrectomy; $n=6$). As seen in the graph, those mice that had the graft removed became hyperglycemic and eventually died (*; end point of death).

Ultra-Structural Analysis of Insulin Producing Cell Clusters

Ultra-structural analysis of the insulin-producing clusters was also performed. An electron-micrograph of BM-derived trans-differentiated cells at a low magnification reveals structures typical of a secretory cell, including rough endoplasmic reticulum, Golgi complex, a few large vacuoles and secretory vesicles containing dense granules (Figure 9a). In addition, microvilli are visible on their surface, which has been described as a characteristic of β -cells.²⁰ Also, many granules seen in the insulin-producing cell clusters exhibited a pale nature with crystalline-like features (Figure 9b). Lastly, immunogold electron microscopy revealed insulin within the small secretory vesicles of the insulin-producing clusters (Figure 9c–g). Gold-labeling detected faint globular structures of differing size filled with floccular, low-density material (Figure 9c) as well as granules with an electron-dense core at the apical pole of the cells (Figure 9d–g). The immunogold labeling of the insulin-producing clusters appears to resemble that of normal pancreatic β -cell, as previously described.²¹ Figure 9h and i represents positive and negative controls for immunogold labeling, respectively. Figure 9h shows INS-1 cells, which is an over expressing cell line, with several positive particles per secretory granule. The INS-1 cells were presented only to validate the assay and not to correlate insulin-positive signal between the INS-1 cells and the BM-derived insulin-producing clusters. The size and location of the gold labeling of




Figure 8 Analysis of graft following kidney excision via immunohistochemistry and ISH for insulin expression. H and E staining of engrafted cells under the kidney capsule reveals that the cells have become cuboidal which is typical of the mature islet cell structure seen in adult pancreas (b) and nontransplanted animal kidney (normal control, a). Insulin staining illustrates that most of the grafted cells are still positive (c). With ISH the grafted cells are positive for expression of the insulin mRNA (d). Nontransplanted kidney tissue as a negative control for ISH (e). (c) and (d) were prepared as serial sections of kidney tissue from BM-derived insulin-producing clusters transplanted animals. The large arrows in (a), (b), (c) and (e) represent the kidney capsule, while the arrowheads indicated positive signals for insulin (d). Original magnification is $\times 60$.

the INS-1 cells closely resembles our insulin-producing clusters. Nonspecific labeling was absent in the nucleus and elsewhere throughout the cell (Figure 9i). The ultrastructural features typical of an adult β -cell found within the insulin-producing clusters suggests these cells may have truly trans-differentiated during culture into β -like cells capable of producing insulin.

Discussion

The data presented demonstrates that adult BM cells appear to trans-differentiate into functional endocrine cells, capable of producing and secreting insulin under high-glucose culture condition. When insulin-producing clusters are transplanted into STZ treated NOD/*scid* mice, blood glucose levels were normalized. Previously, several reports have demonstrated the presence of progenitor cells within pancreatic islets that are capable of differentiating




Figure 9 Electron microscopy and immunoelectron microscopy of BM-derived insulin-producing cell spheroids. Electron microscopy of day 10 insulin-producing cells characterizes their ultrastructure. Secretory granules are densely packed within the cytoplasm of the trans-differentiated cell. Along the cell membrane, microvilli can be seen (a). This has been reported to be another characteristic of mature β -cells. At higher magnification, secretory granules are seen throughout the cytoplasm of the cell (b). The black arrow in (b) indicates crystalline formation within the granular cores. Continued characterization of the trans-differentiated cells through immunogold staining was performed. Postembedding immunogold staining for insulin is shown in (c–g), positive control for immunogold labeling (h) and negative control (i). The positive control is only a representative electron-photomicrograph for the immunogold assay and is not showing a correlation of insulin expression between INS-1 cells and the insulin-producing clusters. Black arrowheads shown in (i) indicate secretory granules illustrating no evidence of insulin expression by the immunogold staining. White arrows shown in (c–g) indicate immunogold particles concentrated in the secretory granules of the trans-differentiated cells. Scale bar, 5 μ m (a, h and i), 1 μ m (b and c) and 0.2 μ m (d)–(g). N, nucleus; V, vacuole; G, granule; MV, microvilli.

into insulin-producing cells.^{15,22} Other reports have stated that hepatic oval cells, embryonic stem cells and splenocyte are capable of differentiating into cells with a pancreatic endocrine phenotype.^{16–18,23} The present report indicates an additional source of cells capable of differentiating into pancreatic endocrine cells both phenotypically and functionally.

Hematopoietic stem cells (HSC), are normally present in adult marrow and have been shown to differentiate into a variety of cell types, including bone, muscle, fat, cartilage, cardiomyocytes, astro-

cytes and hepatic cells.^{5,24–29} Recently, two reports have described the pluripotency of a mesenchymal cell also known as multipotent adult progenitor cells (MAPC). When derived from adult BM, MAPCs can be kept in culture for an extended period of time and can also differentiate into both hepatic and neural lineages.^{30,31} Although HSCs and MAPCs can differentiate into several lineages, to date no pancreatic cells have been described. A recent paper by Lumelsky *et al*¹⁷ demonstrated that embryonic stem cells may possess the ability to become β -like insulin-producing cells. However,

a paper published by Rajagopal *et al*³² observed that these embryonic ' β -like' cells did not produce insulin, but merely took up insulin from the media and subsequently appeared positive for insulin via immunohistochemistry. This finding suggested that several techniques over and above RT-PCR and immunohistochemistry would be necessary to confirm true trans-differentiation of a cell into an insulin-secreting β -cell. These suggestions including the use of both Northern and Western analyses, electron microscopy and long-term animal studies have become the new criteria which investigators must now meet in order to claim that cells have trans-differentiated into functioning β -cells.

Our data demonstrate that adult bone marrow cells can trans-differentiate into functional endocrine cells capable of the production and secretion of physiologically active insulin when cultured under DMSO and high-glucose conditions. The paradigm of BM cell 'trans-differentiation' into multiple cell lineages has been challenged by the observation of cell fusion *in vitro* of pluripotent cells with differentiated cells thus adapting a 'differentiated' phenotype.^{33,34} More recently, two reports have shown that the fusion phenomenon appears to play an important role in a certain type of liver regeneration.^{35,36} These two reports indicate cell fusion as the major mechanism in the regeneration process of the *Fah*^{-/-} liver.^{35,36} However, Ianus *et al*³⁷ recently reported that BM cells could differentiate into β -cells *in vivo* using an elegant Lox/Cre-GFP system demonstrating fusion was not a mechanism in β -cell regeneration. These papers raise several questions as to the role that the type and model of injury may play in dictating the specific processes involved in regenerating the injured organ.

In contrast to what has previously been reported, we have shown that the manipulation of BM cells toward being capable of secreting insulin may be accomplished with relative ease. The trans-differentiation method as presented, only requires 10 days from BM-derived cells to insulin-producing clusters rather than months, thus providing an accessible cell source and a simple method for the cellular treatment of diabetes. In addition, our results illustrate that BM cells can trans-differentiate into a pancreatic lineage *in vitro* without fusion and can function as insulin producing cells both *in vivo* and *in vitro*. It may also be clinically relevant that these cells may not present themselves as fully mature β -cells thereby evading the cycle of β -cell destruction by the immune system. However, further characterization of these cells will be required to determine if this is indeed the case.

In conclusion, our findings present an evidence that BM may include a pancreatic progenitor cell capable of differentiating into functioning endocrine hormone-producing cells. The differentiated cells possess storage granules and produce proinsulin which is cleaved into active insulin in response to

glucose challenge. When transplanted into diabetic mice, the cells retain their properties of storage, processing and regulated secretion of insulin to normalize blood glucose levels. Despite our ability to induce the secretion of detectable levels of insulin *in vitro* in the presence of high glucose by BM-derived insulin-producing clusters, it will be essential to understand what mechanisms are involved during the trans-differentiation process allowing BM cells to mature and differentiate into fully functional β -like cells. Our results suggest that BM cells may provide researchers a powerful tool in the study of pancreatic islet development and function, as well as offering a new potential instrument for the treatment of diabetes.

Acknowledgements

We wish to thank Dr Jill Verlander, Dr Sharon W Matthews, Ms Debbie Akin, Ms Maureen A Petersen, and Ms Stephanie Mauthner for their excellent expertise and assistance in performing electron microscopy and printing the electron micrographs used in Figure 9. We also wish to thank Drs Mark Atkinson and Brant Burkhardt in providing the insulin ELISA results used in Figure 5b, and Dr Sally Litherland for her help in the deconvolution photomicrograph in Figure 6e. National Institute of Health Grants DK60015 and DK58614 awarded to BEP funded this research.

References

- 1 Weissman IL. Translating stem and progenitor cell biology to the clinic: barriers and opportunities. *Science* 2000;287:1442-1446.
- 2 Steindler DA, Pincus DW. Stem cells and neurogenesis in the adult human brain. *Lancet* 2002;359:1047-1054.
- 3 Scott EW, Simon MC, Anastasi J, *et al*. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. *Science* 1994;265:1573-1577.
- 4 Petersen BE, Zajac VF, Michalopoulos GK. Hepatic oval cell activation in response to injury following chemically induced periportal or pericentral damage in rats. *Hepatology* 1998;27:1030-1038.
- 5 Petersen BE, Bowen WC, Patrene KD, *et al*. Bone marrow as a potential source of hepatic oval cells. *Science* 1999;284:1168-1170.
- 6 Theise ND, Badve S, Saxena R, *et al*. Derivation of hepatocytes from bone marrow cells in mice after radiation-induced myeloablation. *Hepatology* 2000;31:235-240.
- 7 Oh SH, Miyazaki M, Kouchi H, *et al*. Hepatocyte growth factor induces differentiation of adult rat bone marrow cells into a hepatocyte lineage *in vitro*. *Biochem Biophys Res Commun* 2000;279:500-504.
- 8 Hellerstrom C. The life story of the pancreatic β -cell. *Diabetologia* 1984;26:393-400.
- 9 Rosenberg L, Vinik AI. Trophic stimulation of the ductular-islet cell axis: a new approach to the

- treatment of diabetes. *Adv Exp Med Biol* 1992;321: 95–104.
- 10 Swenne I. Pancreatic beta-cell growth and diabetes mellitus. *Diabetologia* 1992;35:193–201.
 - 11 Guz Y, Nasir I, Teitelman G. Regeneration of pancreatic beta cells from intra-islet precursor cells in an experimental model of diabetes. *Endocrinology* 2001; 142:4956–4968.
 - 12 Shapiro AM, Lakey JR, Ryan EA, *et al*. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. *N Engl J Med* 2000;343:230–238.
 - 13 Bonner-Weir S, Taneja M, Weir GC, *et al*. *In vitro* cultivation of human islets from expanded ductal tissue. *Proc Natl Acad Sci USA* 2000;97:7999–8004.
 - 14 Halvorsen T, Levine F. Diabetes mellitus—cell transplantation and gene therapy approaches. *Curr Mol Med* 2001;1:273–286.
 - 15 Ramiya VK, Maraist M, Arfors KE, *et al*. Reversal of insulin-dependent diabetes using islets generated *in vitro* from pancreatic stem cells. *Nat Med* 2000;6: 278–282.
 - 16 Yang L, Li S, Hatch H, *et al*. *In vitro* trans-differentiation of adult hepatic stem cells into pancreatic endocrine hormone-producing cells. *Proc Natl Acad Sci USA* 2002;99:8078–8083.
 - 17 Lumelsky N, Blondel O, Laeng P, *et al*. Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets. *Science* 2001;292:1389–1394.
 - 18 Soria B, Roche E, Berna G, *et al*. Insulin-secreting cells derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice. *Diabetes* 2000;49:157–162.
 - 19 Michalopoulos G, Pitot HC. Primary culture of parenchymal liver cells on collagen membranes. Morphological and biochemical observations. *Exp Cell Res* 1975;94:70–78.
 - 20 Orci L, Thorens B, Ravazzola M, *et al*. Localization of the pancreatic beta cell glucose transporter to specific plasma membrane domains. *Science* 1989;245: 295–297.
 - 21 Bendayan M. Ultrastructural localization of insulin and C-peptide antigenic sites in rat pancreatic B cell obtained by applying the quantitative high-resolution protein A-gold approach. *Am J Anat* 1997;185: 205–216.
 - 22 Fernandes A, King LC, Guz Y, *et al*. Differentiation of new insulin-producing cells is induced by injury in adult pancreatic islets. *Endocrinology* 1997;138: 1750–1762.
 - 23 Kodama S, Kuhtreiber W, Fujimura S, *et al*. Islet regeneration during the reversal of autoimmune diabetes in NOD mice. *Science* 2003;302: 1223–1227.
 - 24 Rickard DJ, Sullivan TA, Shenker BJ, *et al*. Induction of rapid osteoblast differentiation in rat bone marrow stromal cell cultures by dexamethasone and BMP-2. *Dev Biol* 1994;161:218–228.
 - 25 Ferrari G, Cusella-De Angelis G, Coletta M, *et al*. Muscle regeneration by bone marrow-derived myogenic progenitors. *Science* 1998;279:1528–1530.
 - 26 Umezawa A, Maruyama T, Segawa K, *et al*. Multipotent marrow stromal cell line is able to induce hematopoiesis *in vivo*. *J Cell Physiol* 1992;151: 197–205.
 - 27 Ashton BA, Allen TD, Howlett CR, *et al*. Formation of bone and cartilage by marrow stromal cells in diffusion chambers *in vivo*. *Clin Orthop* 1980;151: 294–307.
 - 28 Makino S, Fukuda K, Miyoshi S, *et al*. Cardiomyocytes can be generated from marrow stromal cells *in vitro*. *J Clin Invest* 1999;103:697–705.
 - 29 Kopen GC, Prockop DJ, Phinney DG. Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. *Proc Natl Acad Sci USA* 1999;96:10711–10716.
 - 30 Jiang Y, Jahagirdar BN, Reinhardt RL, *et al*. Pluripotency of mesenchymal stem cells derived from adult marrow. *Nature* 2002;418:41–49.
 - 31 Reyes M, Dudek A, Jahagirdar B, *et al*. Origin of endothelial progenitors in human postnatal bone marrow. *J Clin Invest* 2002;109:337–346.
 - 32 Rajagopal J, Anderson WJ, Kume S, *et al*. Insulin staining of ES cell progeny from insulin uptake. *Science* 2003;299:363.
 - 33 Terada N, Hamazaki T, Oka M, *et al*. Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion. *Nature* 2002;416:542–545.
 - 34 Ying QL, Nichols J, Evans EP, *et al*. Changing potency by spontaneous fusion. *Nature* 2002;416:545–548.
 - 35 Wang X, Willenbring H, Akkari Y, *et al*. Cell fusion is the principal source of bone-marrow-derived hepatocytes. *Nature* 2003;422:897–901.
 - 36 Vassilopoulos G, Wang PR, Russell DW. Transplanted bone marrow regenerates liver by cell fusion. *Nature* 2003;422:901–904.
 - 37 Ianus A, Holz GG, Theise ND, *et al*. *In vivo* derivation of glucose-competent pancreatic endocrine cells from bone marrow without evidence of cell fusion. *J Clin Invest* 2003;111:843–850.



Local Production of CTLA4-Ig by Adenoviral-Mediated Gene Transfer to the Pancreas Induces Permanent Allograft Survival and Donor-Specific Tolerance

C. Liu, S. Deng, Z. Yang, T. Kucher, F. Guo, A. Gelman, H. Chen, A. Naji, A. Shaked, and K.L. Brayman

PANCREAS transplantation is a very important therapeutic alternative for type I diabetic patients. Conventionally, systemic immunosuppression has been used to minimize rejection episodes associated with the procedure. However, complications such as infection and malignancy often occur as a result of systemic immunosuppression.¹ Direct expression of immunosuppressive products in the graft may locally inhibit immune responses and minimize systemic toxicity. CTLA4-Ig is a homolog of the CD 28 antigen. It has been shown to inhibit T-cell activation by blocking the costimulatory pathway, and thereby prolong graft survival and produce donor-specific tolerance in some animal transplant models.^{2,3} For our study, we proposed that local immunosuppressive effects may be obtained by local release of CTLA4-Ig from pancreas grafts where the CTLA4-Ig gene was introduced by ex vivo adenoviral-mediated gene transfer.

MATERIALS AND METHODS

AdlacZ and AdCTLA4Ig were constructed by inserting the genes of interest into the viral EI region, rendering the adenovirus replication deficient.⁴ Pancreaticoduodenal grafts were procured and transfected with AdlacZ or AdCTLA4Ig ex vivo via intra-arterial perfusion. Syngeneic AdlacZ-transfected grafts were harvested at various time points after transplantation into streptozotocin (STZ)-induced diabetic recipients, and examined for X-gal staining. Recipients of AdCTLA4Ig-transfected pancreatic allografts were sacrificed at various time points between postoperative days 1 and 42. Transfected grafts as well as several host organs, including liver, spleen, thymus, kidney, and heart, were analyzed for CTLA4-Ig expression by RT-PCR assay and for CTLA4-Ig immunosuppressive ability by morphologic staining. Animals with graft rejection were sacrificed at the time closest to the onset of rejection, and the morphology examined. Simultaneous cotransplantation of different donor strain heart/AdCTLA4Ig-transfected pancreas was also performed.

RESULTS AND DISCUSSION

X-gal staining of tissue sections of AdlacZ-transfected syngeneic pancreatic grafts and host organs demonstrated that the lacZ gene was successfully transferred into the graft, confirming previous observation that arterial perfusion is an efficient method for gene delivery to the pancreas.⁵ LacZ expression was predominantly expressed in the graft, and persisted at a high level for a prolonged period (postoperative days 1 through 28). Some lacZ expression was detected in the host liver; however, this was at a significantly lower level and for shorter period (postoperative days 1 through 7) than in the allograft. Recipient hepatic lacZ expression was undetectable by postoperative day 14. In contrast, graft lacZ expression persisted for 6 weeks. RT-PCR analysis of CTLA4-Ig expression in the AdCTLA4Ig-transfected grafts and several host organs revealed similar results to that of lacZ expression.

Transplantation of control Lewis (untreated, $n = 6$) or AdlacZ-transfected Lewis pancreatic grafts ($n = 4$) into an MHC-incompatible recipient strain (Wistar Furth) gave a mean survival time (MST) of 17 days, while AdCTLA4Ig-transfected pancreatic allografts ($n = 6$) survival was prolonged indefinitely (>180 days). Subsequent donor-strain specific (Lewis) heart transplantation ($n = 3$) did not induce rejection and these hearts were accepted indefi-

From the Department of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania.

The work was supported in part by funds from the Juvenile Diabetes Foundation.

Address reprint requests to Kenneth L. Brayman MD PhD, Department of Surgery, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, Email: brayman@mail.med.upenn.edu.

Table 1. Simultaneous Cotransplantation of AdCTLA4-Ig Transfected Pancreatic Allografts and Naive Cardiac Allografts Into Wistar Furth Diabetic Recipients

Donor Group	Recipient Group	n	P Survival Days	Ht Survival Days	H MST
P (Lew) + Ht(ACI)	WF	5	$>100 \times 5$	7, 7, 8, 9, 9	8
P (ACI) + Ht(Lew)	WF	3	$>100 \times 3$	21, 23, 25	23

Abbreviations: P, pancreatic allograft group; Ht, naive cardiac allograft group.

626

LIU, DENG, YANG ET AL

nitely, while third party cardiac allografts (ACI, n = 6) were rejected.

Cotransplantation of AdCTLA4Ig-transfected pancreatic graft (P) and naive cardiac grafts (Ht) was performed to determine the local versus systemic effect of the locally delivered CTLA4-Ig. As shown in Table 1, AdCTLA4Ig-transfected pancreatic grafts survived indefinitely while the naive third-party cardiac allografts were rejected.

CONCLUSION

Ex vivo arterial perfusion of adenoviral vectors into the pancreas can lead to successful viral infection and localized gene transfer. AdCTLA4Ig-transfection of pancreas trans-

plants results in indefinite survival of the allograft, and induces donor-specific tolerance in the transplant recipient. Cotransplantation experiments confirm the local immunosuppressive effect of the transferred CTLA4-Ig gene, and its ability to produce long-term graft survival and donor-specific tolerance in the rat pancreas transplantation model.

REFERENCES

1. Sutherland DE, et al: Diabetes Metabolism Rev 11:337, 1995
2. Lenschow DJ, et al: Science 257:789, 1992
3. Turka LA, et al: Proc Natl Acad Sci USA 89:11102, 1992
4. Olthoff KM, et al: Nature Med 4:194, 1998
5. Deng S, et al: Diabetes 58:A67, 1998



Evidence That the Adenoviral Vector Containing the CTLA4-Ig Gene Improves Transgene Expression and Graft Survival

Y. Namii, S. Hayashi, I. Yokoyama, T. Kobayashi, M. Yasutomi, T. Nagasaka, K. Uchida, H. Hamada, and H. Takagi

REJECTION of organ allografts is dependent on T cell activation, which requires T-cell receptor engagement by antigen and costimulatory signals delivered by T-cell surface molecules such as CD28. CTLA4-Ig is a recombinant fusion protein that contains the extracellular domain of human CTLA4 (a homologue of CD28) fused to a human IgG₁ heavy chain. It has previously been shown to block the CD28-mediated costimulatory signal and to inhibit immune responses in vitro and in vivo.^{1,2}

Recently, the replication-defective adenovirus vector has been shown to be efficient in transferring exogenous genes into a variety of cells both in vitro and in vivo.³ In this study, we examined the ability of adenovirus vector containing CTLA4-Ig (Adex/CTLA4-Ig) to modify the rejection process observed in ACI to LEW rats liver transplantation.

MATERIALS AND METHODS

Animals

Inbred male LEW(RT1^b) and ACI (RT1^a) rats, weighing 220 to 300g were used as transplant recipients and donors, respectively. The animals were maintained under standard conditions and were fed water and rodent chow ad libitum.

Liver Transplantation

Orthotopic liver transplantation (OLT) was performed under ether anesthesia using the two-cuff technique as described by Kamada and Calne.⁴

Adenovirus Vector

The replication-defective recombinant adenovirus encoding the *Escherichia coli* LacZ gene, capable of producing the enzyme β -galactosidase was used as control vector (Adex/LacZ). The recombinant adenovirus (Adex/hCTLA4-Ig) containing the expression cassette for the human CTLA4-Ig cDNA was constructed by homologous recombination between the expression cosmid cassette (pAdex/CAhCTLA4-Ig) and the parental virus genome. The method of generating recombinant adenovirus was a modification described by Saito et al.⁵ The recombinant viruses were subsequently propagated with 293 cells and viral solution was stored at -80°C.

Experimental Group and Vector Transfection

Donor ACI rats were administered via the penile vein with a volume of 1×10^9 plaque-forming units of recombinant adenovirus

containing LacZ gene (group 1; n = 5) or CTLA4-Ig gene (group 2; n = 5). Seven days after infection, genetically modified livers were harvested and transplanted into LEW rats. Both groups of recipients were not given any other immunosuppressive agents. There was no significant difference in the length of preservation and portal vein occlusion time between the groups.

RESULTS

In the ACI-to-LEW liver grafting combination (group 2) in whom donor livers were transduced by Adex/CTLA4-Ig significantly prolonged graft survival (14<, 20<, 21<, 55, 61< d) was shown than in the control group (all rejected within 13 days). Microscopic findings in the transplanted liver on day 9 in group 1 revealed marked infiltration of mononuclear cells in the portal tracts whereas this was less remarkable in group 2.

DISCUSSION

In this experimental model of liver transplantation, genetic modification of the donor liver by Adex/CTLA4-Ig resulted in a statistically significant prolongation of graft survival. The different pattern of effectiveness may be related to the intensity of transduction, which indicates that insufficient transgene expression may have caused the loss of tolerance. Because of this, our method of administration via the penile vein of donor is justified. Many preliminary studies in rats and mice have shown that administration of adenoviral vectors via a peripheral vein results in more efficient transduction of hepatocytes as compared with other organs in 10- to 100-fold less amount of vector per cell. Moreover, the donor livers can be transduced with ease during the harvesting or preservation phases of surgery.⁶

In conclusion, our methods of adenovirus-mediated gene transfer to donor liver is feasible, because it modulates local

From the Department of Surgery II, Nagoya University School of Medicine, Nagoya, Japan (Y.N., S.H., I.Y., T.K., M.Y., T.N., H.T.), Nagoya 2nd Red Cross Hospital, Nagoya, Japan (K.U.), and the Department of Molecular Biotherapy Research, Cancer Chemotherapy Center, Tokyo, Japan (H.H.)

Address reprint requests to Yasushi Namii, Department of Surgery II, Nagoya University School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466, Japan.

0041-1315/97/\$17.00
PII S0041-1345(97)00038-9

© 1997 by Elsevier Science Inc.
655 Avenue of the Americas, New York, NY 10010

ADENOVIRAL VECTOR CONTAINING THE CTLA4-IG GENE

1739

immune response through the production of therapeutic proteins. Thus, the immunologic manipulation of donor liver appears to be an attractive method and has a potential of clinical application in the strategy for liver transplantation.

REFERENCES

1. Linsky PS, Wallace PM, Johnson J, et al: Science 257:792, 1992
2. Pearson T, Alexander D, Winn K, et al: Transplantation 57:1701, 1994
3. Hayashi S, Kojima T, et al: Transplant Proc 28:215, 1996
4. Kamada N, Calne R: Transplantation 28:47, 1979
5. Saito I, Oya Y, Yamamoto K, et al: J Virol 54:711, 1985
6. Shaked A, Cscto M, Drazan K, et al: Transplantation 57:1508, 1994